Market Snapshot

BSE Sensex: 74616.58 0.69%
BSE 500: 33395.05 0.50%
BSE 200: 10527.75 0.56%
BSE 100: 24268.91 0.62%
BSE BANKEX: 59308.33 0.21%
BSE IT: 30158.03 2.37%
Nifty 50: 23123.65 0.68%
Nifty 500: 21296.45 0.48%
Nifty 200: 12958.15 0.56%
Nifty 100: 23730.25 0.64%
Nifty Midcap 100: 54600.55 0.20%
Nifty Small 100: 15843.3 -0.06%
Nifty IT: 31403.35 2.50%
Nifty PSU Bank: 8264.8 -0.71%

News:

AB Real Estate arm clocks Rs 6...
Unimech Aerospace reports heal...
PNGS Gargi Fashion Jewellery s...
Jubilant Foodworks Ltd leads l...
United Drilling Tools gains on...

Hester Biosciences Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

Invest

07 Apr 2026 | 04:14 PM

1,426.90

10.10 (0.71%)

Add to Watchlist

This awesome feature is still in our labs.
Set Alert

This awesome feature is still in our labs.

Underperforms Index

-13.87%

Return (1Y)

Underperformed Nifty 50 by 18.21%
More Volatile

2.13%

Standard Deviation (1Y)

Higher than Nifty 50 by 1.29%
Not so consistent

4/12

Months

underperformed Nifty 50
AxisDirect View

No View

52 Week High-Low

2,350

1,239

News & Announcements

Hester Biosciences to divest over 43% stake in Texas Lifesciences for Rs 9.2 crore
28 days ago

Hester Biosciences to divest over 43% stake in Texas Lifesciences for Rs 9.2 crore

11 - Mar - 2026 12:00 | 28 days ago

The company?s currently holds around 54.81% stake in Texas Lifesciences.
Texas Lifesciences had recorded a turnover of Rs 28.59 crore and its net worth was Rs 13.41 crore in FY2024-25.
Offering details of this transaction, the company stated that the 43.81% shareholding of Hester will be transferred to Ticop Life, an entity affiliated to the existing promoter shareholders of TLPL.
Hester will continue to do business with TLPL and maintain an 11% equity stake in the company.
The company expects to conclude this transaction within a period of three months from the date of this agreement. It will receive a consideration of Rs 9.2 crore as a part of this transaction.
Hester Biosciences Limited is one of the India?s leading animal health company, manufacturing vaccines and health products. It is the second largest poultry vaccine manufacturer, with approximately 35% market share in India.
The company had reported 24.79% fall in consolidated net profit to Rs 8.77 crore despite a 22.46% increase in revenue to Rs 77.42 crore in Q3 FY26 as compared with Q3 FY25.
The scrip fell 0.17% to currently trade at Rs 1450.00 on the BSE.

Powered by Capital Market - Live News
Hester Biosciences to divest stake in Texas Lifesciences
28 days ago

Hester Biosciences to divest stake in Texas Lifesciences

11 - Mar - 2026 12:00 | 28 days ago

The board of Hester Biosciences at its meeting held on 11 March 2026 has approved the divestment of 43.81% equity stake out of total 54.81% in its subsidiary, Texas Lifesciences (TLPL), by way of transfer/sale of shares to the existing promoter shareholders of the TLPL for a consideration of Rs 9.2 crore.
TLPL is not material subsidiary of the Company. TLPL will ceased to be the subsidiary of the Company upon completion share transfer transaction as above.
Hester will continue to do business with TLPL and maintain an 11% equity stake/investment in the company.
Powered by Capital Market - Live News
Hester Biosciences consolidated net profit declines 24.79% in the December 2025 quarter
68 days ago

Hester Biosciences consolidated net profit declines 24.79% in the December 2025 quarter

30 - Jan - 2026 12:00 | 68 days ago

Net profit of Hester Biosciences declined 24.79% to Rs 8.77 crore in the quarter ended December 2025 as against Rs 11.66 crore during the previous quarter ended December 2024. Sales rose 22.46% to Rs 77.42 crore in the quarter ended December 2025 as against Rs 63.22 crore during the previous quarter ended December 2024.

Particulars Quarter Ended
Dec. 2025 Dec. 2024 % Var.

Sales 77.42 63.22 22

OPM % 22.99 8.02 -

PBDT 17.96 17.66 2

PBT 13.52 13.37 1

NP 8.77 11.66 -25

Powered by Capital Market - Live News
Hester Biosciences to announce Quarterly Result
76 days ago

Hester Biosciences to announce Quarterly Result

22 - Jan - 2026 12:00 | 76 days ago

Hester Biosciences will hold a meeting of the Board of Directors of the Company on 30 January 2026.
Powered by Capital Market - Live News

Price vs Volume

Stock Trivia

MF shareholding in Hester Biosciences Ltd has increased by 5.56% since past 3 Months
FII shareholding in Hester Biosciences Ltd has decreased by -13.32% since past 1 Year
MF shareholding in Hester Biosciences Ltd has increased by 11.76% since past 1 Year

Peer Comparison on Risk - Return

Thanks for Liking, Please spread your love by sharing...

Particulars	Quarter Ended
	Dec. 2025	Dec. 2024	% Var.
Sales	77.42	63.22	22
OPM %	22.99	8.02	-
PBDT	17.96	17.66	2
PBT	13.52	13.37	1
NP	8.77	11.66	-25

General Notifications

My Notifications

Research Notifications

Hester Biosciences Ltd Share Price – NSE / BSE Pharmaceuticals, Small Cap

1,426.90 10.10 (0.71%)

News & Announcements

Price vs Volume

Stock Trivia

Hester Biosciences Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

1,426.90

10.10 (0.71%)